

Supplementary material to article by T. Lejeune et al. "AbobotulinumtoxinA injections in shoulder muscles to improve adult upper limb spasticity: Results from a phase 4 real-world study and a phase 3 open-label trial"

ABOBOTULINUMTOXINA INJECTIONS IN SHOULDER MUSCLES TO IMPROVE ADULT UPPER LIMB SPASTICITY: RESULTS FROM A PHASE 4 REAL-WORLD STUDY AND A PHASE 3 OPEN-LABEL TRIAL

Thierry LEJEUNE, MD, PhD^{a,*}, Svetlana KHATKOVA, MD, PhD^c, Lynne TURNER-STOKES, MD, FRCP^{d,e}, Philippe PICAUT, PharmD^f, Pascal MAISONOBE, MSc^g, Jovita BALCAITIENE, MD^h, François Constant BOYER, MD, PhDⁱ, on behalf of the International AbobotulinumtoxinA Adult Upper Limb Spasticity (AUL) and Upper Limb International Spasticity II (ULIS-II) Study Groups

From the ^aUniversité Catholique de Louvain, Secteur des Sciences de la Santé, Institut de Recherche Expérimentale et Clinique, NeuroMusculoSkeletalLab (NMSK), Brussels, Belgium, ^bCliniques Universitaires Saint-Luc, Service de médecine physique et réadaptation, Brussels, Belgium, ^cNeurology Department, Federal State Hospital Treatments and Rehabilitation Center of the Ministry of Health and Social Development of the Russian Federation, Moscow, Russia, ^dDepartment of Palliative Care, Policy and Rehabilitation, Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK, ^eRegional Hyper-acute Rehabilitation Unit, Northwick Park Hospital, London, UK, ^fIpsen Bioscience, Cambridge, MA, USA, ^gIpsen Pharma, Boulogne-Billancourt, France, ^hUniversité de Reims Champagne-Ardenne, Hôpital Sébastopol, Centre Hospitalier Universitaire de Reims, Physical Medicine and Rehabilitation Department, Reims, France and ⁱSee study groups listed below

STUDY GROUPS

ULIS-II investigators

Australia: Steven Faux, Brian Zeman, Clayton King, Ian Baguley, Arun Aggarwal, Michael Pollack; Austria: Klemens Fheodoroff, Johann Rappold; Belgium: Els Van Tcihelt, Geert Vanhooren, Thierry Deltombe, Thierry Lejeune; Czech Republic: Edvard Ehler, Martin Bares; Denmark: Thomas Truelsen; Finland: Petteri Maunu, Niko Tieranta, Jari Ylinen; France: Claire Aynard, Isabelle Bonan, François Constant Boyer, Jean-Yves Salle, Dominique Perennou, Anne-Laure Ferrapie, Nicolas Bayle, Marie-Eve Isner-Horobeti, Claire Delleci, Sedar Kocer, Bernard Parratte, Joanna Rome, Laurent Bensoussan, Christophe Roth; Germany: Gerhard Reichel, Peter Kossmehl, Hartwig Woldag, Dirk Dressler, Beate Patzner, Stefan Unglaub; Hong Kong: Leonard Sheung Wai Li; Italy: Franco Molteni, Giovanni Checchia, Marzia Millevolte, Manuela Diverio, Carmelo Chisari, Mario Manca; Malaysia: Goh Khean-Jin, Mak Choon Soon; Mexico: Francisco Jiménez, Carlos Cuevas; Philippines: Raymond Rosales, Jeanne Flordelis; Portugal: Jorge Jacinto, Maria João Andrade, Ana Rolo Duarte, Eduarda Afonso, Renato Nunes; Russian Federation: Svetlana Khatkova, Dina Khasanova, Ludmila Korenko, Ludmila Antipova, Larisa Sperling, Dmitry Popov, Dmitry Pokhabov; Singapore: Kong Keng He, Ng Yee Sein; South Korea: Kim Deog Young, Yun Hee Kim, Nam Jong Paik, Sang Jee Lee, Min Ho Chun; Spain: Inmaculada Mániz Añón, Susana Moraleda Pérez, Lourdes López de Munain; Sweden: Bo Danielsson, Ann Axelsson; Taiwan: Tsai Ching Piao, Chou Li Wei; Thailand: Witansu Kumthornthip, Areerat Suputtitada; United Kingdom: Rama Prasad, Thevanandham Lal Landham, Prabal Datta, Magid Bakheit, Lynne Turner-Stokes.

AUL open-label study group

Belgium: Thierry Deltombe, Thierry Lejeune; Czech Republic: Robert Jech, Petr Kanovsky; France: François Constant Boyer, Philippe Marque, Djamel Bensmail, Sedar Kocer, Jean-Michel Gracies, Pierre Decavel, Marie-Eve Isner-Horobeti, Olivier Remy-Neris; Hungary: Zoltan Denes, Attila Csányi, László Vécsei; Italy: Michele Vecchio, Anna Rita Bentivoglio; Poland: Marta Banach, Anna Kaminska, Monika Rudinzska; Russian Federation: Svetlana Khatkova, Alexander Skoromets, Sofia Timerbaeva; Slovakia: Peter Valkovic; United States: Allison Brashear, Steven Edgley, David Simpson, Michael O'Dell, Gerard Francisco, Peter McAllister, Peter Hedera, Heather Walker, Fatma Gul, Bruce Rubin, Ziyad Ayyoub, Christina Marciniak, Stuart Isaacson, Michael Wimmer.

Table SI. Doses of abobotulinumtoxinA injected in each shoulder muscle in the (A) Upper Limb International Spasticity-II (ULIS-II) study and (B) Adult Upper Limb (AUL) open-label study

(A) Shoulder muscles	ULIS-II study n=82	(B) AUL open-label study				
		Cycle 1 n=35	Cycle 2 n=67	Cycle 3 n=57	Cycle 4 n=33	
Pectoralis major, n (%)	63 (76.8)	23 (65.7)	52 (77.6)	48 (84.2)	30 (90.9)	
Units, median (IQR) [range]	200.0 (150.0) [30–750]	168.3 (47.5)	226.0 (52.1)	227.7 (65.3)	224.0 (69.4)	
Deltoideus, n (%)	14 (17.1)	[100–260]	[100–300]	[100–500]	[100–500]	
Units, median (IQR) [range]	100.0 (100.0) [50–300]	11 (31.4)	31 (46.3)	32 (56.1)	13 (39.4)	
Triceps brachii, n (%)	10 (12.2)	Mean (SD)	200 (0)	194.5 (70.6)	193.4 (65.5)	175.4 (51.7)
Units, median (IQR) [range]	175.0 (100.0) [60–300]	[range]	[200–200]	[100–400]	[0–300]	[100–260]
Subscapularis, n (%)	8 (9.8)	Triceps brachii, n (%)	12 (34.3)	29 (43.3)	23 (40.4)	10 (30.3)
Units, median (IQR) [range]	200.0 (100.0) [75–320]	Mean (SD)	150.0 (67.4)	184.8 (69.2)	186.1 (58.9)	194.0 (92.9)
Teres major, n (%)	7 (8.5)	[range]	[100–300]	[80–300]	[100–300]	[80–300]
Units, median (IQR) [range]	75.0 (50.0) [50–200]	Subscapularis, n (%)	4 (11.4)	17 (25.4)	18 (31.6)	10 (30.3)
Rhomboids, n (%)	6 (7.3)	Mean (SD)	175.0 (50)	147.6 (59.5)	122.8 (60.6)	130.0 (48.3)
Units, median (IQR) [range]	150.0 (0) [150–400]	[range]	[100–200]	[100–300]	[0–260]	[100–200]
Latissimus dorsi, n (%)	3 (3.7)	IQR: interquartile range; SD: standard deviation.				
Units, median (IQR) [range]	120.0 (125.0) [75–200]					
Trapezius upper, n (%)	3 (3.7)					
Units, median (IQR) [range]	100.0 (100.0) [100–200]					
Supraspinatus, n (%)	1 (1.2)					
Units, median (IQR) [range]	100.0 (0) [100–100]					
Teres minor, n (%)	1 (1.2)					
Units, median (IQR) [range]	100.0 (0) [100–100]					